Tags

Type your tag names separated by a space and hit enter

Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis.
Expert Opin Pharmacother. 2019 May; 20(7):805-811.EO

Abstract

INTRODUCTION

Osteoporosis is a skeletal disorder characterized by loss of bone mass and strength affecting up to 30-50% of postmenopausal women worldwide. Current therapeutic options include antiresorptives such as aminobisphosphonates or denosumab and osteoanabolic compounds such as teriparatide. Areas covered: In this review, the authors summarize the clinical development, safety and efficacy profile of abaloparatide, a new osteoanabolic agent recently marketed in the US for the treatment of postmenopausal osteoporosis in women who are at high risk for fracture or who fail antiresorptive therapy. Expert opinion: Abaloparatide is a 1-34 PTH related peptide-like molecule that has been modified in order to potentiate the osteoanabolic effect. In its pivotal phase 3 trial in postmenopausal women with osteoporosis, subcutaneous abaloparatide 80 mcg/day reduced the risk of vertebral, nonvertebral, major osteoporotic, and clinical fractures compared with placebo and reduced the risk of major osteoporotic fractures compared with teriparatide. These results, together with a reduced prevalence of hypercalcemia and a lower cost of the marketed compound, point toward improved cost effectiveness with abaloparatide versus teriparatide. However, some concerns have been raised due to a somewhat higher occurrence of adverse effects (particularly with palpitations and increased heart rate) or the resultant discontinuation due to these adverse effects when compared to teriparatide.

Authors+Show Affiliations

a Department of Medicine, Surgery and Neurosciences , University of Siena , Siena , Italy.b EndOsMet , Villa Donatello Private Hospital , Florence , Italy. c Unit for Bone Metabolism Diseases and Diabetes and Lab of Endocrine and Metabolic Research , IRCCS Istituto Auxologico Italiano , Milan , Italy.c Unit for Bone Metabolism Diseases and Diabetes and Lab of Endocrine and Metabolic Research , IRCCS Istituto Auxologico Italiano , Milan , Italy. d Department of Medical Science and Community Health , University of Milan , Milan , Italy.a Department of Medicine, Surgery and Neurosciences , University of Siena , Siena , Italy.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

30856013

Citation

Merlotti, D, et al. "Efficacy and Safety of Abaloparatide for the Treatment of Post-menopausal Osteoporosis." Expert Opinion On Pharmacotherapy, vol. 20, no. 7, 2019, pp. 805-811.
Merlotti D, Falchetti A, Chiodini I, et al. Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis. Expert Opin Pharmacother. 2019;20(7):805-811.
Merlotti, D., Falchetti, A., Chiodini, I., & Gennari, L. (2019). Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis. Expert Opinion On Pharmacotherapy, 20(7), 805-811. https://doi.org/10.1080/14656566.2019.1583208
Merlotti D, et al. Efficacy and Safety of Abaloparatide for the Treatment of Post-menopausal Osteoporosis. Expert Opin Pharmacother. 2019;20(7):805-811. PubMed PMID: 30856013.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis. AU - Merlotti,D, AU - Falchetti,A, AU - Chiodini,I, AU - Gennari,L, Y1 - 2019/03/11/ PY - 2019/3/12/pubmed PY - 2019/6/6/medline PY - 2019/3/12/entrez KW - Abaloparatide KW - bone formation KW - osteoporosis treatment KW - postmenopausal osteoporosis KW - teriparatide SP - 805 EP - 811 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 20 IS - 7 N2 - INTRODUCTION: Osteoporosis is a skeletal disorder characterized by loss of bone mass and strength affecting up to 30-50% of postmenopausal women worldwide. Current therapeutic options include antiresorptives such as aminobisphosphonates or denosumab and osteoanabolic compounds such as teriparatide. Areas covered: In this review, the authors summarize the clinical development, safety and efficacy profile of abaloparatide, a new osteoanabolic agent recently marketed in the US for the treatment of postmenopausal osteoporosis in women who are at high risk for fracture or who fail antiresorptive therapy. Expert opinion: Abaloparatide is a 1-34 PTH related peptide-like molecule that has been modified in order to potentiate the osteoanabolic effect. In its pivotal phase 3 trial in postmenopausal women with osteoporosis, subcutaneous abaloparatide 80 mcg/day reduced the risk of vertebral, nonvertebral, major osteoporotic, and clinical fractures compared with placebo and reduced the risk of major osteoporotic fractures compared with teriparatide. These results, together with a reduced prevalence of hypercalcemia and a lower cost of the marketed compound, point toward improved cost effectiveness with abaloparatide versus teriparatide. However, some concerns have been raised due to a somewhat higher occurrence of adverse effects (particularly with palpitations and increased heart rate) or the resultant discontinuation due to these adverse effects when compared to teriparatide. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/30856013/Efficacy_and_safety_of_abaloparatide_for_the_treatment_of_post_menopausal_osteoporosis_ L2 - https://www.tandfonline.com/doi/full/10.1080/14656566.2019.1583208 DB - PRIME DP - Unbound Medicine ER -